NAGE - Niagen Operating income before deduction of amortization

Public company logo of ChromaDex Corp (NAGE)

The EBITDA of Chromadex Corp (NAGE) reflects cash flow dynamics, where the current parameter equals 4.84. Growth is constrained by strict FDA oversight regarding Tru Niagen marketing. However, Niagen patents ensure leadership in cellular energy. A steady inflow of funds is guaranteed by a recurring sales model for dietary supplements via online channels and retail.

niagenbioscience.com (NAGE) - Profit before payment of interest, taxes and amortization from 11/23/2025 to 11/11/2026

Summary analytical data breakdowns for ChromaDex Corp (NAGE)

- stock quotes and analyst forecast:
Price Performance Chart ChromaDex|NAGE - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization ChromaDex|NAGE - Total Company Value
- balance sheet equity data:
Equity per Share ChromaDex|NAGE - Company Book Value|Market Capitalization to Book Value niagenbioscience.com|NAGE - Cumulative Company Assets
- debt level and financial liquidity data:
Aggregate Debt to Capital Chromadex Corp|NAGE - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Niagen|NAGE - Company Total Debt|Debts to Book Capitalization ChromaDex|NAGE - Company Long-Term Debt|Company Current Liabilities ChromaDex|Immediate Liquidity niagenbioscience.com
- earnings and valuation multiples indicators:
NAGE - Company Net Income|Net Profit Forecast Chromadex Corp|NAGE - Price to Earnings Ratio|Market Cap to Future Earnings Ratio niagenbioscience.com|NAGE - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio ChromaDex|NAGE - Operating profit EBITDA|Net earnings per share for the last 12 months ChromaDex|NAGE - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months niagenbioscience.com|NAGE - Earnings per share growth in current year|Expected earnings per share trend next year Chromadex Corp
Fundamental company valuation:NAGE (Chromadex Corp)
Product sample of ChromaDex Corp

This indicator reflects the actual cash inflow from core operations before deducting interest expenses. The metric eliminates reporting time lags, capturing the daily operational efficiency of the business. Analyzing EBITDA fluctuations allows for tracking real-time cash flow dynamics between quarterly reports. For Chromadex Corp (NAGE), this confirms financial stability during the commercialization of patented dietary supplements. High liquidity here is based on deep consumer trust in science-intensive products.

Competitors of Chromadex Corp (NAGE)

Income before deduction of interest, taxes and amortization ISRG|Danaher Corp. - Operating profit EBITDA|Operating income before deduction of amortization bd.com BDX|STERIS (STE) - Profit before payment of interest, taxes and amortization|Operating profit before amortization WST|Profit before payment of interest, taxes and amortization Baxter Corp|Masimo Inc. (MASI) - Operating income before deduction of amortization|Operating profit before deduction of amortization STVN (Stevanato Group S.p.A.)|Company profit before taxes, interest and amortization TFX|Profit before payment of interest, taxes and amortization Merit Medical MMSI|Income before deduction of interest, taxes and amortization NVST|ICUI: Operating profit before deduction of amortization|XRAY - Operating profit EBITDA|LeMaitre Vascular, Inc. (LMAT) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization atricure.com|STAA (STAAR Surgical) - Operating profit EBITDA|Profit before interest, taxes and amortization ZimVie Inc ZIMV|Profit before payment of interest, taxes and amortization AngioDynamics Corp (ANGO)|Cerus Inc - Operating profit before amortization|Alpha Teknova, Inc. - Operating profit before deduction of amortization|Company profit before taxes, interest and amortization MGRM (monogramorthopedics.com)|STSS - Profit before payment of interest, taxes and amortization|Operating income before deduction of amortization InfuSystem Holdings INFU|UTMD: Operating profit EBITDA|Operating profit before deduction of amortization KORU Medical|NYXH (Nyxoah S.A.) - Operating profit EBITDA|MBOT: Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Pro-Dex (PDEX)|ZTEK (Zentek Ltd) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization Elutia Corp ELUT|Milestone Scientific Corporation (MLSS) - Profit before interest, taxes and amortization|NXGL - Profit before payment of interest, taxes and amortization|Retractable Technologies (RVP) - Operating profit before deduction of amortization|HBIO: Operating profit EBITDA|Femasys Inc (FEMY) - Operating profit EBITDA|MHUA (Meihua Medical Technologies) - Operating profit EBITDA|Operating profit before amortization POAI (Predictive Oncology Corp)|Operating profit EBITDA CJMB|ATRI - Profit before interest, taxes and amortization|NeuroMetrix - Operating profit before deduction of amortization